GTC
VRDN icon

Ghost Tree Capital’s Viridian Therapeutics VRDN Stock Holding History

Ghost Tree Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.71M Sell
75,000
-512,708
-87% -$8.38M 0.52% 49
2024
Q2 		$7.65M Sell
587,708
-37,292
-6% -$516K 2.39% 16
2024
Q1 		$10.9M Buy
625,000
+325,000
+108% +$6.3M 3.03% 8
2023
Q4 		$6.53M Buy
300,000
+25,000
+9% +$395K 2.14% 11
2023
Q3 		$4.22M Buy
275,000
+35,000
+15% +$668K 1.39% 25
2023
Q2 		$5.71M Buy
240,000
+65,000
+37% +$1.67M 1.88% 20
2023
Q1 		$4.45M Buy
175,000
+10,000
+6% +$321K 1.32% 29
2022
Q4 		$4.82M Sell
165,000
-370,000
-69% -$8.52M 2.06% 19
2022
Q3 		$11M Sell
535,000
-65,000
-11% -$1.17M 3.08% 13
2022
Q2 		$6.94M Buy
600,000
+133,597
+29% +$1.8M 3.62% 12
2022
Q1 		$8.62M Sell
466,403
-33,597
-7% -$646K 1.87% 10
2021
Q4 		$9.88M Buy
500,000
+150,000
+43% +$2.79M 3.54% 8
2021
Q3 		$5.76M Hold
350,000
– – 1.68% 20
2021
Q2 		$6.4M Buy
350,000
+50,000
+17% +$856K 1.76% 19
2021
Q1 		$5.01M Buy
+300,000
New +$5.62M 1.18% 31

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ghost Tree Capital's VRDN Position: Q3 2024 in Review

Ghost Tree Capital reduced its Viridian Therapeutics (VRDN) stake by 87% in Q3 2024, selling an estimated $8.38M and leaving 75,000 shares worth $1.71M. The position accounts for 0.52% of the portfolio, ranked #49.

Ghost Tree Capital first reported a position in VRDN in Q1 2021 and has held it in 15 quarters since. The position peaked at $11M in Q3 2022. 165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

  • Ghost Tree Capital held 75,000 shares of Viridian Therapeutics worth $1.71M as of Q3 2024.
  • Ghost Tree Capital sold 512,708 Viridian Therapeutics shares in Q3 2024, an estimated $8.38M.
  • Viridian Therapeutics made up 0.52% of Ghost Tree Capital's portfolio in Q3 2024, its #49 holding.
  • Ghost Tree Capital first reported a position in Viridian Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Ghost Tree Capital's Viridian Therapeutics position peaked at $11M in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.